Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 299, Issue 4, 2010, Pages

  Vera, Trinity ^a   Stec, David E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Bilirubin; Glomerular filtration rate; Indinavir; Morpholino; Renal blood flow; UGT1A1

Indexed keywords

ANGIOTENSIN II; ANTISENSE OLIGONUCLEOTIDE; BILIRUBIN; INDINAVIR; IOTALAMIC ACID I 125; GLUCURONOSYLTRANSFERASE; MORPHOLINE DERIVATIVE; OATP2 PROTEIN, MOUSE; ORGANIC CATION TRANSPORTER; PROTEIN SYNTHESIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HYPERBILIRUBINEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; KIDNEY CIRCULATION; LIVER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; BILIRUBIN; BLOTTING, WESTERN; GLOMERULAR FILTRATION RATE; GLUCURONOSYLTRANSFERASE; HYPERBILIRUBINEMIA; HYPERTENSION; INDINAVIR; LIVER; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; OLIGONUCLEOTIDES, ANTISENSE; ORGANIC CATION TRANSPORT PROTEINS; PROTEIN SYNTHESIS INHIBITORS; RENAL CIRCULATION;

EID: 77957597205     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00316.2010     Document Type: Article

References (37)

1. Botros FT, Schwartzman ML, Stier CT Jr, Goodman AI, Abraham NG. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int 68: 2745-2755, 2005.
2. Bruce RG, Munch LC, Hoven AD, Jerauld RS, Greenburg R, Porter WH, Rutter PW. Urolithiasis associated with the protease inhibitor indinavir. Urology 50: 513-518, 1997.
3. Chin HJ, Cho HJ, Lee TW, Na KY, Oh KH, Joo KW, Yoon HJ, Kim YS, Ahn C, Han JS, Kim S, Jeon ES, Jin DC, Kim YL, Park SH, Kim CD, Song YR, Kim SG, Kim YG, Lee JE, Oh YK, Lim CS, Lee SK, Chae DW, Cho WY, Kim HK, Jo SK. The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy. J Korean Med Sci 24 Suppl: S22-S29, 2009.
4. Chin HJ, Song YR, Kim HS, Park M, Yoon HJ, Na KY, Kim Y, Chae DW, Kim S. The bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci 24 Suppl: S50-S56, 2009.
5. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 103: 17985-17990, 2006.
6. Folkers G. Two new protease inhibitors approved by FDA. Food and Drug Administration. NIAID AIDS Agenda March: 4-5, 1996.
7. Ghem C, Sarmento-Leite RE, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. Int Heart J 51: 86-91, 2010.
8. Hall JE. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol Regul Integr Comp Physiol 250: R960-R972, 1986.
9. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16: 250-255, 1996.
10. Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev 42: 53-59, 2010.
11. Kohan AD, Armenakas NA, Fracchia JA. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 161: 1765-1768, 1999.
12. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114: 1476-1481, 2006.
13. Morcos PA, Li Y, Jiang S. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 45: 613-4, 616, 618, 2008.
14. Nath KA, d'Uscio LV, Juncos JP, Croatt AJ, Manriquez MC, Pittock ST, Katusic ZS. An analysis of the DOCA-salt model of hypertension in HO-1-/- mice and the Gunn rat. Am J Physiol Heart Circ Physiol 293: H333-H342, 2007.
15. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 228: 568-571, 2003.
16. Pflueger A, Croatt AJ, Peterson TE, Smith LA, d'Uscio LV, Katusic ZS, Nath KA. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 288: F552-F558, 2005.
17. Quan S, Yang L, Shnouda S, Schwartzman ML, Nasjletti A, Goodman AI, Abraham NG. Expression of human heme oxygenase-1 in the thick ascending limb attenuates angiotensin II-mediated increase in oxidative injury. Kidney Int 65: 1628-1639, 2004.
18. Quintino MP, Simoes RS, Oliveira FH, Oliveira-Filho RM, Simoes MJ, Nakamura MU, Kulay L Jr. Morphological and biochemical appraisal of the liver and renal effects of indinavir on rat pregnancy. Clin Exp Obstet Gynecol 34: 232-235, 2007.
19. Ruan X, Oliverio MI, Coffman TM, Arendshorst WJ. Renal vascular reactivity in mice: ANG II-induced vasoconstriction in AT1A receptor null mice. J Am Soc Nephrol 10: 2620-2630, 1999.
20. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. Angiotensin II-induced vascular dysfunction is mediated by the AT1A receptor in mice. Hypertension 43: 1074-1079, 2004.
21. Ryan MJ, Jernigan NL, Drummond HA, McLemore GR Jr, Rimoldi JM, Poreddy SR, Gadepalli RS, Stec DE. Renal vascular responses to CORM-A1 in the mouse. Pharmacol Res 54: 24-29, 2006.
22. Sabaawy HE, Zhang F, Nguyen X, ElHosseiny A, Nasjletti A, Schwartzman M, Dennery P, Kappas A, Abraham NG. Human heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats. Hypertension 38: 210-215, 2001.
23. Saltel E, Angel JB, Futter NG, Walsh WG, O'Rourke K, Mahoney JE. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 164: 1895-1897, 2000.
24. Stec DE, Vera T, McLemore GR Jr, Kelsen S, Rimoldi JM, Gadepalli RS, Ryan MJ. Heme oxygenase-1 induction does not improve vascular relaxation in Angiotensin II hypertensive mice. Am J Hypertens 21: 189-193, 2008.
25. Stec DE, Vera T, Storm MV, McLemore GR Jr., Ryan MJ. Blood pressure and renal blow flow responses in heme oxygenase-2 knockout mice. Am J Physiol Regul Integr Comp Physiol 297: R1822-R1828, 2009.
26. Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal 6: 841-849, 2004.
27. Summerton JE. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 7: 651-660, 2007.
28. Tallam LS, Kuo JJ, da Silva AA, Hall JE. Cardiovascular, renal, and metabolic responses to chronic central administration of agouti-related peptide. Hypertension 44: 853-858, 2004.
29. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 336: 138-140, 1997.
30. Traynor TR, Schnermann J. Renin-angiotensin system dependence of renal hemodynamics in mice. J Am Soc Nephrol 10 Suppl 11: S184-S188, 1999.
31. Vera T, Granger JP, Stec DE. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol 297: R738-R743, 2009.
32. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension 45: 730-735, 2005.
33. Yang L, Quan S, Abraham NG. Retrovirus-mediated HO gene transfer into endothelial cells protects against oxidant-induced injury. Am J Physiol Lung Cell Mol Physiol 277: L127-L133, 1999.
34. Yang L, Quan S, Nasjletti A, Laniado-Schwartzman M, Abraham NG. Heme oxygenase-1 gene expression modulates angiotensin II-induced increase in blood pressure. Hypertension 43: 1221-1226, 2004.
35. Zhang D, Wang L, Chandrasena G, Ma L, Zhu M, Zhang H, Davis CD, Humphreys WG. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos 35: 139-149, 2007.
36. Zhao D, Seth DM, Navar LG. Enhanced distal nephron sodium reabsorption in chronic angiotensin II-infused mice. Hypertension 54: 120-126, 2009.
37. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98: 12671-12676, 2001.